rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-537-546rsp-3072Research ArticleПЕРЕДОВАЯLEADING ARTICLEНовые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I)New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович

115522, Российская Федерация, Москва, Каширское шоссе, 34а;

119991, Российская Федерация, Москва, ул. Трубецкая, 8, стр. 2

Evgeny Nasonov

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A;

119991, Russian Federation, Moscow, Trubetskaya str., 8, building 2

nasonov@irramn.ruhttps://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

Anastasia S. Avdeeva

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

Tatiana V. Popkova

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202107102021595537546Copyright © Насонов Е.Л., Авдеева А.С., Попкова Т.В., 20212021Насонов Е.Л., Авдеева А.С., Попкова Т.В.Nasonov E.L., Avdeeva A.S., Popkova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3072

Системная красная волчанка (СКВ) – системное аутоиммунное ревматическое заболевание неизвестной этиологии, характеризующееся гиперпродукцией органонеспецифических аутоантител к различным молекулам клеточного ядра и развитием иммуновоспалительного повреждения внутренних органов. По современным представлениям, один из ключевых механизмов иммунопатогенеза СКВ связан с нарушениями регуляции синтеза интерферона (ИФН) типа I. Комплекс данных, полученных в процессе фундаментальных и клинических исследований, послужил основанием для разработки нового подхода к фармакотерапии СКВ, связанного с использованием моноклональных антител (мАТ), блокирующих активность ИФН типа I или его рецепторов. В ряду этих препаратов особое место занимает анифролумаб (АФМ) (ранее известный как MEDI-546), представляющий собой человеческие IgG1 к мАТ, связывающиеся с клеточными рецепторами для ИФН-α. В статье рассматриваются материалы основных исследований, касающихся эффективности и безопасности АФМ при СКВ, и перспективы применения этого препарата в лечении данного заболевания.

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern concepts, one of the key mechanisms of SLE immunopathogenesis is associated with dysregulation of type I interferon (IFN) synthesis The complex of data obtained in the process of fundamental and clinical research served as the basis for the development of a new approach to the pharmacotherapy of SLE, associated with the use of monoclonal antibodies (mAbs) that block the activity of IFN type I or its receptors. Among these drugs, anifrolumab (AFM) occupies a special place, which is a human IgG1 mAbs that bind to cellular receptors for IFN-α. The article discusses the materials of the main studies concerning the efficacy and safety of AFM in SLE, and the prospects for the use of this drug in the treatment of this disease.

системная красная волчанкиинтерферонгенно-инженерные биологические препаратыанифролумабsystemic lupus erythematosusinterferongenetically engineered biological drugsanifrolumabReferencesKaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019;6(1):e000310. doi: 10.1136/lupus-2018-000310Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019;6(1):e000310. doi: 10.1136/lupus-2018-000310Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-2343. doi: 10.1016/S0140-6736(19)30237-5Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-2343. doi: 10.1016/S0140-6736(19)30237-5Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK. Unchanging premature mortality trends in systemic lupus erythematosus: A general population-based study (1999–2014). Rheumatology (Oxford). 2018;57(2):337-344. doi: 10.1093/rheumatology/kex412Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK. Unchanging premature mortality trends in systemic lupus erythematosus: A general population-based study (1999–2014). Rheumatology (Oxford). 2018;57(2):337-344. doi: 10.1093/rheumatology/kex412Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-XDörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-XCrow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369-393. doi: 10.1146/annurev-pathol-020117-043952Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369-393. doi: 10.1146/annurev-pathol-020117-043952Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270Schoggins JW. Interferon-stimulated genes: What do they all do? Annu Rev Virol. 2019;6(1):567-584. doi: 10.1146/annurev-virology-092818-015756Schoggins JW. Interferon-stimulated genes: What do they all do? Annu Rev Virol. 2019;6(1):567-584. doi: 10.1146/annurev-virology-092818-015756Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: A complex web of host defenses. Annu Rev Immunol. 2014;32:513-545. doi: 10.1146/annurev-immunol-032713-120231Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: A complex web of host defenses. Annu Rev Immunol. 2014;32:513-545. doi: 10.1146/annurev-immunol-032713-120231Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214(5):1547-1555. doi: 10.1084/jem.20161451Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214(5):1547-1555. doi: 10.1084/jem.20161451Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, et al. Ultrasensitive serum interferon-alpha quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis. 2019;78(12):1669-1676. doi: 10.1136/annrheumdis-2019-215571Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, et al. Ultrasensitive serum interferon-alpha quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis. 2019;78(12):1669-1676. doi: 10.1136/annrheumdis-2019-215571Bondet V, Rodero MP, Posseme C, Bost P, Decalf J, Haljasmägi L, et al. Differential levels of IFNα subtypes in autoimmunity and viral infection. Cytokine. 2021;144:155533. doi: 10.1016/j.cyto.2021.155533Bondet V, Rodero MP, Posseme C, Bost P, Decalf J, Haljasmägi L, et al. Differential levels of IFNα subtypes in autoimmunity and viral infection. Cytokine. 2021;144:155533. doi: 10.1016/j.cyto.2021.155533Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43-48. doi: 10.1016/j.semarthrit.2020.11.006Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43-48. doi: 10.1016/j.semarthrit.2020.11.006Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128Mai L, Asaduzzaman A, Noamani B, Fortin PR, Gladman DD, Touma Z, et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23(1):29. doi: 10.1186/s13075-021-02414-0Mai L, Asaduzzaman A, Noamani B, Fortin PR, Gladman DD, Touma Z, et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23(1):29. doi: 10.1186/s13075-021-02414-0Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491-1503. doi: 10.1002/art.21031Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491-1503. doi: 10.1002/art.21031Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044-1053. doi: 10.1002/art.30187Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044-1053. doi: 10.1002/art.30187Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962. doi: 10.1002/art.22044Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962. doi: 10.1002/art.22044Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-yOke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-yLandolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(9):1440-1446. doi: 10.1136/ard.2008.093146Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(9):1440-1446. doi: 10.1136/ard.2008.093146Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009;18(11):980-989. doi: 10.1177/0961203309105529Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009;18(11):980-989. doi: 10.1177/0961203309105529Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(3):551-565. doi: 10.1016/j.cell.2016.03.008Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(3):551-565. doi: 10.1016/j.cell.2016.03.008Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66(6):1583-1595. doi: 10.1002/art.38628Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66(6):1583-1595. doi: 10.1002/art.38628Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS, et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics. 2019;12(1):4. doi: 10.1186/s12920-018-0468-1Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS, et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics. 2019;12(1):4. doi: 10.1186/s12920-018-0468-1Wither J, Johnson SR, Liu T, Noamani B, Bonilla D, Lisnevskaia L, et al. Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther. 2017;19(1):41. doi: 10.1186/s13075-017-1243-yWither J, Johnson SR, Liu T, Noamani B, Bonilla D, Lisnevskaia L, et al. Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther. 2017;19(1):41. doi: 10.1186/s13075-017-1243-yHua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54(6):1906-1916. doi: 10.1002/art.21890Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54(6):1906-1916. doi: 10.1002/art.21890Kennedy WP, Maciuca R, Wolslegel K, Tew W, Abbas AR, Chaivorapol C, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med. 2015;2(1):e000080. doi: 10.1136/lupus-2014-000080Kennedy WP, Maciuca R, Wolslegel K, Tew W, Abbas AR, Chaivorapol C, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med. 2015;2(1):e000080. doi: 10.1136/lupus-2014-000080Menon M, Bradford HF, Haljasmagi L, Vanker M, Peterson P, Wincup C, et al. Inactive disease in lupus patients is linked to autoantibodies to type-I interferons that normalize blood IFNα and B cell subsets. medRxiv. 2021;04.07.21255049. doi: 10.1101/2021.04.07.21255049Menon M, Bradford HF, Haljasmagi L, Vanker M, Peterson P, Wincup C, et al. Inactive disease in lupus patients is linked to autoantibodies to type-I interferons that normalize blood IFNα and B cell subsets. medRxiv. 2021;04.07.21255049. doi: 10.1101/2021.04.07.21255049Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653-1664. doi: 10.1136/annrheumdis-2018-213197Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653-1664. doi: 10.1136/annrheumdis-2018-213197Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012;166(5):971-975. doi: 10.1111/j.1365-2133.2012.10825.xBraunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012;166(5):971-975. doi: 10.1111/j.1365-2133.2012.10825.xNzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:1579-1588. doi: 10.1002/art.22578Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:1579-1588. doi: 10.1002/art.22578Castellano G, Cafiero C, Divella C, Sallustio F, Gigante M, Pontrelli P, et al. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther. 2015;17(1):72. doi: 10.1186/s13075-015-0588-3Castellano G, Cafiero C, Divella C, Sallustio F, Gigante M, Pontrelli P, et al. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther. 2015;17(1):72. doi: 10.1186/s13075-015-0588-3Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992;35(4):417-422. doi: 10.1002/art.1780350410Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferonalpha in lupus psychosis. Arthritis Rheum. 1992;35(4):417-422. doi: 10.1002/art.1780350410Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020;29(9):1025-1041. doi: 10.1080/13543784.2020.1797677Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020;29(9):1025-1041. doi: 10.1080/13543784.2020.1797677Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. Clin Rheumatol. 2021;40(8):3027-3037. doi: 10.1007/s10067-020-05526-1Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. Clin Rheumatol. 2021;40(8):3027-3037. doi: 10.1007/s10067-020-05526-1Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(4):519-528. doi: 10.1080/14712598.2021.1841164Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(4):519-528. doi: 10.1080/14712598.2021.1841164Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-439. doi: 10.1080/19420862.2015.1007810Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-439. doi: 10.1080/19420862.2015.1007810Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Lin Chia Y, Santiago L, Wang B, Kuruvilla D, Wang S, Tummala R, et al. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2021 Feb 25:keab176. doi: 10.1093/rheumatology/keab176Lin Chia Y, Santiago L, Wang B, Kuruvilla D, Wang S, Tummala R, et al. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2021 Feb 25:keab176. doi: 10.1093/rheumatology/keab176Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(6):854-858. doi: 10.1136/ard.2004.029058Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(6):854-858. doi: 10.1136/ard.2004.029058Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther. 2012;14(6):R244. doi: 10.1186/ar4087Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther. 2012;14(6):R244. doi: 10.1186/ar4087Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 2009;60(10):3098-3107. doi: 10.1002/art.24803Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 2009;60(10):3098-3107. doi: 10.1002/art.24803Sjöstrand M, Johansson A, Aqrawi L, Olsson T, Wahren-Herlenius M, Espinosa A. The expression of BAFF is controlled by IRF transcription factors. J Immunol. 2016;196(1):91-96. doi: 10.4049/jimmunol.1501061Sjöstrand M, Johansson A, Aqrawi L, Olsson T, Wahren-Herlenius M, Espinosa A. The expression of BAFF is controlled by IRF transcription factors. J Immunol. 2016;196(1):91-96. doi: 10.4049/jimmunol.1501061Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210. doi: 10.1002/art.27189.Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210. doi: 10.1002/art.27189.Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816-825. doi: 10.1002/art.41598Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816-825. doi: 10.1002/art.41598Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Jayne D, Rovin BH, Mysler E, Furie R, Houssiau F, Trasieva T, et al. POS0690 Randomized, controlled, phase 2 trial of type 1 IFN inhibitor anifrolumab in patients with active proliferative lupus nephritis. Ann Rheum Dis. 2021;80:592.Jayne D, Rovin BH, Mysler E, Furie R, Houssiau F, Trasieva T, et al. POS0690 Randomized, controlled, phase 2 trial of type 1 IFN inhibitor anifrolumab in patients with active proliferative lupus nephritis. Ann Rheum Dis. 2021;80:592.Tummala R, Rouse T, Berglind A, Santiago L. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252. doi: 10.1136/lupus-2017-000252Tummala R, Rouse T, Berglind A, Santiago L. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252. doi: 10.1136/lupus-2017-000252Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30(1):101-108. doi: 10.1080/14397595.2019.1583833Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30(1):101-108. doi: 10.1080/14397595.2019.1583833Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-1543. doi: 10.2147/DDDT.S170969Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-1543. doi: 10.2147/DDDT.S170969Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod Rheumatol. 2021;31(1):1-12. doi: 10.1080/14397595.2020.1812201Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod Rheumatol. 2021;31(1):1-12. doi: 10.1080/14397595.2020.1812201Koh JWH, Ng CH, Tay SH. Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials. Lupus. 2020;29(14):1845-1853. doi: 10.1177/0961203320959702.Koh JWH, Ng CH, Tay SH. Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials. Lupus. 2020;29(14):1845-1853. doi: 10.1177/0961203320959702.Lee YH, Song GG. Anifrolumab for the treatment of active systemic lupus erythematosus: A meta-analysis of randomized controlled trials. Z Rheumatol. 2020 Nov 20. doi: 10.1007/s00393-020-00928-7Lee YH, Song GG. Anifrolumab for the treatment of active systemic lupus erythematosus: A meta-analysis of randomized controlled trials. Z Rheumatol. 2020 Nov 20. doi: 10.1007/s00393-020-00928-7Abdul Razzack A, Abdul Razzack S, Shenasan P, Shenasan N, Mishra S, Zarrar R, et al. POS0701 Anifrolumab, an anti-interferon-α receptor monoclonal antibody in systemic lupus erythematosus – A meta-analysis. Ann Rheum Dis. 2021;80:600. doi: 10.1136/annrheumdis-2021-eular.2782Abdul Razzack A, Abdul Razzack S, Shenasan P, Shenasan N, Mishra S, Zarrar R, et al. POS0701 Anifrolumab, an anti-interferon- α receptor monoclonal antibody in systemic lupus erythematosus – A meta-analysis. Ann Rheum Dis. 2021;80:600. doi: 10.1136/annrheumdis-2021-eular.2782Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021;30(8):1254-1263. doi: 10.1177/09612033211014267Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021;30(8):1254-1263. doi: 10.1177/09612033211014267Merrill JT, Werth V, Furie R, Morand E, Kahlenberg J, Abreu G, et al. OP0131 Anifrolumab effects on rash and arthritis in patients with SLE and impact of interferon signal in pooled data from phase 3 trials. Ann Rheum Dis. 2021;80:75-76. doi: 10.1136/annrheumdis-2021-eular.1471Merrill JT, Werth V, Furie R, Morand E, Kahlenberg J, Abreu G, et al. OP0131 Anifrolumab effects on rash and arthritis in patients with SLE and impact of interferon signal in pooled data from phase 3 trials. Ann Rheum Dis. 2021;80:75-76. doi: 10.1136/annrheumdis-2021-eular.1471Isenberg D, Bruce IN, Furie R, Morand EF, Tanaka Y, Manzi S, et al. POS0683 Novel stringent outcome measures applied to the phase 2 and 3 anifrolumab trials. Ann Rheum Dis. 2021;80:586-587. doi: 10.1136/annrheumdis-2021-eular.702Isenberg D, Bruce IN, Furie R, Morand EF, Tanaka Y, Manzi S, et al. POS0683 Novel stringent outcome measures applied to the phase 2 and 3 anifrolumab trials. Ann Rheum Dis. 2021;80:586-587. doi: 10.1136/annrheumdis-2021-eular.702Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, et al. What does it mean to be a british isles lupus assessment group-based composite lupus assessment responder? Post hoc analysis of 2 phase 3 trials. Arthritis Rheumatol. 2021 Apr 28. doi: 10.1002/art.41778Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, et al. What does it mean to be a british isles lupus assessment group-based composite lupus assessment responder? Post hoc analysis of 2 phase 3 trials. Arthritis Rheumatol. 2021 Apr 28. doi: 10.1002/art.41778Furie R, Kalunian K, Merrill J, Abreu G, Tummala R. Lupus disease activity after cessation of anifrolumab treatment during the phase 2b MUSE trial follow-up period [abstract]. Arthritis Rheumatol. 2020; 72(Suppl 10). URL: https://acrabstracts.org/abstract/lupus-disease-activity-after-cessation-of-anifrolum-ab-treatment-during-the-phase-2b-muse-trial-follow-up-periodFurie R, Kalunian K, Merrill J, Abreu G, Tummala R. Lupus disease activity after cessation of anifrolumab treatment during the phase 2b MUSE trial follow-up period [abstract]. Arthritis Rheumatol. 2020; 72(Suppl 10). URL: https://acrabstracts.org/abstract/lupus-disease-activity-after-cessation-of-anifrolumab-treatment-during-the-phase-2b-muse-trial-follow-up-periodMorand EF, Furie R, Tanaka Y, Takeuchi T, Abreu G, Tummala R, et al. POS0691 Effects of anifrolumab on renal disease in patients with SLE. Ann Rheum Dis. 2021;80:592-593. doi: 10.1136/annrheumdis-2021-eular.1618Morand EF, Furie R, Tanaka Y, Takeuchi T, Abreu G, Tummala R, et al. POS0691 Effects of anifrolumab on renal disease in patients with SLE. Ann Rheum Dis. 2021;80:592-593. doi: 10.1136/annrheumdis-2021-eular.1618Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2018;30(5):441-448. doi: 10.1097/BOR.0000000000000528Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2018;30(5):441-448. doi: 10.1097/BOR.0000000000000528Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med. 2020;217(1):e20190459. doi: 10.1084/jem.20190459Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med. 2020;217(1):e20190459. doi: 10.1084/jem.20190459Marieke C, Boshuizen S, de Winther MPJ. Interferons as essential modulators of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(7):1579-1588. doi: 10.1161/ATVBAHA.115.305464Marieke C, Boshuizen S, de Winther MPJ. Interferons as essential modulators of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(7):1579-1588. doi: 10.1161/ATVBAHA.115.305464Kirchler C, Husar-Memmer E, Rappersberger K, Thaler K, Fritsch-Stork R. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review. Autoimmun Rev. 2021;20(5):102794. doi: 10.1016/j.autrev.2021.102794Kirchler C, Husar-Memmer E, Rappersberger K, Thaler K, Fritsch-Stork R. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review. Autoimmun Rev. 2021;20(5):102794. doi: 10.1016/j.autrev.2021.102794Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, et al. Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(3):459-471. doi: 10.1002/art.41518Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, et al. Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(3):459-471. doi: 10.1002/art.41518Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018;3(8):e99276. doi: 10.1172/jci.insight.99276Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018;3(8):e99276. doi: 10.1172/jci.insight.99276Moore S, Juo HH, Nielsen CT, Tyden H, Bengtsson AA, Lood C. Neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus. J Rheumatol. 2019;47:1652-1660.Moore S, Juo HH, Nielsen CT, Tyden H, Bengtsson AA, Lood C. Neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus. J Rheumatol. 2019;47:1652-1660.Purmalek MM, Carlucci PM, Dey AK, Sampson M, Temesgen-Oyelakin Y, Sakhardande S, et al. Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE. Lupus Sci Med. 2019;6(1):e000332. doi: 10.1136/lupus-2019-000332Purmalek MM, Carlucci PM, Dey AK, Sampson M, Temesgen- Oyelakin Y, Sakhardande S, et al. Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE. Lupus Sci Med. 2019;6(1):e000332. doi: 10.1136/lupus-2019-000332Cates AM, Holden VI, Myers EM, Smith CK, Kaplan MJ, Kahlenberg JM. Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors. Rheumatology (Oxford). 2015;54(6):1114-1123. doi: 10.1093/rheumatology/keu431Cates AM, Holden VI, Myers EM, Smith CK, Kaplan MJ, Kahlenberg JM. Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors. Rheumatology (Oxford). 2015;54(6):1114-1123. doi: 10.1093/rheumatology/keu431Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, et al. Safety profile of anifrolumab in patients with active SLE: An integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi: 10.1136/lupus-2020-000464Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, et al. Safety profile of anifrolumab in patients with active SLE: An integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi: 10.1136/lupus-2020-000464Merrill J, Kalunian K, Furie R, Winthrop K, Primakov P, Pineda L, et al. Herpes zoster events with anifrolumab in patients with active SLE: An integrated analysis of phase 2 and phase 3 trials [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10). https://acrabstracts.org/abstract/herpes-zoster-events-with-anifrolumab-in-patients-with-active-sle-an-integrated-analysis-of-phase-2-and-phase-3-trials.Merrill J, Kalunian K, Furie R, Winthrop K, Primakov P, Pineda L, et al. Herpes zoster events with anifrolumab in patients with active SLE: An integrated analysis of phase 2 and phase 3 trials [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10). https://acrabstracts.org/abstract/herpes-zoster-events-with-anifrolumabin-patients-with-active-sle-an-integrated-analysis-of-phase-2-and-phase-3-trials.Toro-Domínguez D, Alarcón-Riquelme ME. Precision medicine in autoimmune diseases: Fact or fiction. Rheumatology (Oxford). 2021 May 18:keab448. doi: 10.1093/rheumatology/keab448Toro-Domínguez D, Alarcón-Riquelme ME. Precision medicine in autoimmune diseases: Fact or fiction. Rheumatology (Oxford). 2021 May 18:keab448. doi: 10.1093/rheumatology/keab448Lever E, Alves MR, Isenberg DA. Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med. 2020;13:39-49. doi: 10.2147/PGPM.S205079Lever E, Alves MR, Isenberg DA. Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med. 2020;13:39-49. doi: 10.2147/PGPM.S205079Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Northcott M, Gearing LJ, Nim HT, Nataraja C, Hertzog P, Jones SA, et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: A cross-sectional and in-vitro study. Lancet Rheumatol. 2021;3(5):e357-e370. doi: 10.1016/S2665-9913(21)00006-0Northcott M, Gearing LJ, Nim HT, Nataraja C, Hertzog P, Jones SA, et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: A cross-sectional and in-vitro study. Lancet Rheumatol. 2021;3(5):e357-e370. doi: 10.1016/S2665-9913(21)00006-0Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247. doi: 10.1038/nri.2017.1Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247. doi: 10.1038/nri.2017.1Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med. 2019;216(2):384-406. doi: 10.1084/jem.20180595Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med. 2019;216(2):384-406. doi: 10.1084/jem.20180595van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y-J, Lateef A, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: A multicentre cohort study. Lancet Rheumatol. 2020;2:e24-e30. doi: 10.1016/S2665-9913(19)30105-5Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y-J, Lateef A, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: A multicentre cohort study. Lancet Rheumatol. 2020;2:e24-e30. doi: 10.1016/S2665-9913(19)30105-5Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207-216. doi: 10.1093/rheumatology/keaa267Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207-216. doi: 10.1093/rheumatology/keaa267Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev. 2018;17(1):4-10. doi: 10.1016/j.autrev.2017.11.002Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev. 2018;17(1):4-10. doi: 10.1016/j.autrev.2017.11.002van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554561. doi: 10.1136/annrheumdis-2016-209519van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford). 2018;57(8):1370-1376. doi: 10.1093/rheumatology/key103Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford). 2018;57(8):1370-1376. doi: 10.1093/rheumatology/key103Touma Z, Gladman DD, Zandy M, Su J, Anderson N, Urowitz MB. Identifying a response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. Arthritis Care Res (Hoboken). 2020 May 20. doi: 10.1002/acr.24261Touma Z, Gladman DD, Zandy M, Su J, Anderson N, Urowitz MB. Identifying a response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. Arthritis Care Res (Hoboken). 2020 May 20. doi: 10.1002/acr.24261Gao H, Wang Q, Yu X, Liu J, Bai S, Feng J, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review. Life Sci. 2018;209:383-387. doi: 10.1016/j.lfs.2018.08.038Gao H, Wang Q, Yu X, Liu J, Bai S, Feng J, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review. Life Sci. 2018;209:383-387. doi: 10.1016/j.lfs.2018.08.038Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465(7300):937-941. doi: 10.1038/nature09102Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465(7300):937-941. doi: 10.1038/nature09102Lepelletier Y, Zollinger R, Ghirelli C, Raynaud F, HadjSlimane R, Cappuccio A, et al. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood. 2010;116(18):3389-3397. doi: 10.1182/blood-2010-05-282913Lepelletier Y, Zollinger R, Ghirelli C, Raynaud F, Hadj-Slimane R, Cappuccio A, et al. Toll-like receptor control of glucocorticoid- induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood. 2010;116(18):3389-3397. doi: 10.1182/blood-2010-05-282913Felger JC, Haroon E, Woolwine BJ, Raison CL, Miller AH. Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiol Behav. 2016;166:14-21. doi: 10.1016/j.physbeh.2015.12.013Felger JC, Haroon E, Woolwine BJ, Raison CL, Miller AH. Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiol Behav. 2016;166:14-21. doi: 10.1016/j.physbeh.2015.12.013

The authors declare that there are no conflicts of interest present.